Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Down 23.5% in February

Addex Therapeutics Ltd (NASDAQ:ADXN) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 1,300 shares, a decline of 23.5% from the February 13th total of 1,700 shares. Based on an average daily volume of 19,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are sold short.

Hedge Funds Weigh In On Addex Therapeutics

A hedge fund recently bought a new stake in Addex Therapeutics stock. Citadel Advisors LLC acquired a new position in shares of Addex Therapeutics Ltd (NASDAQ:ADXN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,079 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 1.14% of Addex Therapeutics at the end of the most recent quarter. Institutional investors own 16.14% of the company’s stock.

Addex Therapeutics Stock Performance

Shares of ADXN opened at $7.42 on Wednesday. The company has a 50-day simple moving average of $7.73 and a 200-day simple moving average of $8.74. Addex Therapeutics has a 52 week low of $6.67 and a 52 week high of $27.90. The firm has a market capitalization of $7.87 million, a P/E ratio of -21.82 and a beta of 1.76.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.